The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Myeloma highlights at ASH 2022: BiTEs, CAR-T therapy, novel targets, and more
Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, shares some highlights in myeloma from the 2022 ASH Annual Meeting, commenting on the exciting data around bispecific T-cell engagers (BiTEs), including talquetamab, cevostamab and elranatamab. Dr Raje also discusses novel targets being explored, and promising results demonstrated with the use of CAR-T therapy, including the success of idecabtagene vicleucel (ide-cel). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
